Evaluation of the effectiveness of the orexin receptor antagonist for type 2 diabetes with sleep disorder upon glycemic control.
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Suvorexant (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 05 Feb 2018 Status changed from not yet recruiting to discontinued.
- 18 Apr 2017 New trial record